Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
ConditionLymphoma, Non-Hodgkin's, Adult
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorSalarius Pharmaceuticals, LLC
About this trial
The purpose of this research is to help researchers find out if SP-3164 is safe and if it may be of benefit in the treatment of patients with Non-Hodgkin's lymphoma that has progressed after prior treatment, or that never responded to previous treatment.
Eligibility criteria
Qualifiers
require treatment in the opinion of the Investigator
received at least 2 lines of systemic therapy for B-cell NHL
Disqualifiers
None
Trial design
Treatments tested in this trial
- SP-3164
Treatment groups
72 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov